Myeloablative radioimmunotherapy using 131I-tositumomab (anti-CD20) monoclonal
antibodies is an effective therapy for B-cell non-Hodgkin's lymphoma. The amount of …

Radioimmunotherapy (RIT) using 131I-tositumomab has been used successfully to treat
relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). Our approach to treatment …

The majority of patients with relapsed or refractory B-cell, non-Hodgkin's lymphoma (NHL)
are over 60 years of age, yet many are denied potentially curative high-dose regimens due …

The study aimed at identifying patient-specific dosimetric and nondosimetric factors
predicting outcome of non-Hodgkin lymphoma patients after 131I-tositumomab …

A methodology was developed determining patient releasability after radioimmunotherapy
with tositumomab and 131I-tositumomab for the treatment of non-Hodgkin's lymphoma …

Radioimmunotherapy (RIT) is a promising emerging therapy for non-Hodgkin's lymphoma
and may ultimately prove useful in the treatment of other tumors. The most extensively …

Tositumomab and 131 I-tositumomab constitute a relatively new radioimmunotherapeutic
regimen for patients with CD20+ follicular non-Hodgkin's lymphoma (NHL). Currently, it is …

277 Objectives: Anti CD-20 Radioimmunotherapy is useful at non-myeloablative doses for
many patients with chemotherapy refractory low grade and transformed low grade …

With the success of targeted monoclonal antibody therapy in non-Hodgkin's lymphoma,
attempts were made to further improve efficacy through the addition of a radioisotope. A goal …

Radioimmunotherapy (RIT) treatment for lymphoma is a novel targeted therapeutic
approach. Several years of development of radioimmunotherapeutic compounds came to …